Molecular and Cellular Mechanisms of Ecstasy-Induced Neurotoxicity: An Overview
暂无分享,去创建一个
Andreas Meisel | F. Carvalho | A. Meisel | F. Remião | M. Bastos | Helena Carmo | Félix Carvalho | H. Carmo | Fernando Remião | João Paulo Capela | Maria Lourdes Bastos | J. Capela
[1] Renata M. Wentzcovitch,et al. Effect of the d electrons on phase transitions in transition-metal sesquioxides , 2011, PCM 2011.
[2] R. Altman,et al. Cytochrome P450 2D6. , 2009, Pharmacogenetics and genomics.
[3] Teresa Summavielle,et al. PRECLINICAL STUDY: Ecstasy‐induced oxidative stress to adolescent rat brain mitochondria in vivo: influence of monoamine oxidase type A , 2009, Addiction biology.
[4] M. Meyer,et al. The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxyethylamphetamine and Its Single Enantiomers , 2009, Drug Metabolism and Disposition.
[5] R. Wyeth,et al. The hyperthermia mediated by 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) is sensitive to sex differences. , 2009, Toxicology and applied pharmacology.
[6] N. Ballatori,et al. Plasma membrane glutathione transporters and their roles in cell physiology and pathophysiology. , 2009, Molecular aspects of medicine.
[7] E. Fernandes,et al. Acetyl-l-carnitine provides effective in vivo neuroprotection over 3,4-methylenedioximethamphetamine-induced mitochondrial neurotoxicity in the adolescent rat brain , 2009, Neuroscience.
[8] V. M. Costa,et al. Cross-functioning between the extraneuronal monoamine transporter and multidrug resistance protein 1 in the uptake of adrenaline and export of 5-(glutathion-S-yl)adrenaline in rat cardiomyocytes. , 2009, Chemical research in toxicology.
[9] K. Lesch,et al. Differential long-term effects of MDMA on the serotoninergic system and hippocampal cell proliferation in 5-HTT knock-out vs. wild-type mice. , 2008, The international journal of neuropsychopharmacology.
[10] S. Kato,et al. Risperidone attenuates and reverses hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats. , 2008, Neurotoxicology.
[11] S. Schenk,et al. Acute and sensitized response to 3,4‐methylenedioxymethamphetamine in rats: different behavioral profiles reflected in different patterns of Fos expression , 2008, The European journal of neuroscience.
[12] J. Duarte,et al. Chronic exposure to ethanol exacerbates MDMA-induced hyperthermia and exposes liver to severe MDMA-induced toxicity in CD1 mice. , 2008, Toxicology.
[13] M. Yliperttula,et al. Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[14] H. Galons,et al. Sprague–Dawley rats display metabolism-mediated sex differences in the acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) , 2008 .
[15] U. McCann,et al. Nonlinear Pharmacokinetics of (±)3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) and Its Major Metabolites in Squirrel Monkeys at Plasma Concentrations of MDMA That Develop After Typical Psychoactive Doses , 2008, Journal of Pharmacology and Experimental Therapeutics.
[16] E. Jaehne,et al. The effect of long-term repeated exposure to 3,4-methylenedioxymethamphetamine on cardiovascular and thermoregulatory changes , 2008, Psychopharmacology.
[17] K. Bost,et al. Ecstasy (3,4-methylenedioxymethamphetamine) limits murine gammaherpesvirus-68 induced monokine expression , 2008, Brain, Behavior, and Immunity.
[18] Marilyn A Huestis,et al. Physiological and Subjective Responses to Controlled Oral 3,4-Methylenedioxymethamphetamine Administration , 2008, Journal of clinical psychopharmacology.
[19] M. Austin,et al. 3,4-Methylenedioxymethamphetamine induces differential regulation of tryptophan hydroxylase 2 protein and mRNA levels in the rat dorsal raphe nucleus , 2008, Neuroscience.
[20] Z. Szabo,et al. Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (±)3,4-methylenedioxymethamphetamine (“ecstasy”) users: relationship to cognitive performance , 2008, Psychopharmacology.
[21] U. Dirnagl,et al. 5,7-Dihydroxitryptamine toxicity to serotonergic neurons in serum free raphe cultures. , 2008, European journal of pharmacology.
[22] Olga Valverde,et al. CB1Cannabinoid Receptor Modulates 3,4-Methylenedioxymethamphetamine Acute Responses and Reinforcement , 2008, Biological Psychiatry.
[23] J. Camarasa,et al. Memantine protects against amphetamine derivatives-induced neurotoxic damage in rodents , 2008, Neuropharmacology.
[24] Koki Ito,et al. Olanzapine and risperidone block a high dose of methamphetamine-induced schizophrenia-like behavioral abnormalities and accompanied apoptosis in the medial prefrontal cortex , 2008, Schizophrenia Research.
[25] R. Torre,et al. On the role of tyrosine and peripheral metabolism in 3,4-methylenedioxymethamphetamine-induced serotonin neurotoxicity in rats , 2008, Neuropharmacology.
[26] Natalie D Eddington,et al. Fluoxetine pretreatment effects pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, ECSTASY) in rat. , 2008, Journal of pharmaceutical sciences.
[27] Frederick H. Franken,et al. Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges , 2008, Neuroscience.
[28] Andrea Caricasole,et al. Enhanced Tau Phosphorylation in the Hippocampus of Mice Treated with 3,4-Methylenedioxymethamphetamine (“Ecstasy”) , 2008, The Journal of Neuroscience.
[29] P. Robledo,et al. MDMA modifies active avoidance learning and recall in mice , 2008, European Neuropsychopharmacology.
[30] T. Monks,et al. Modulation of Human Multidrug Resistance Protein (MRP) 1 (ABCC1) and MRP2 (ABCC2) Transport Activities by Endogenous and Exogenous Glutathione-Conjugated Catechol Metabolites , 2008, Drug Metabolism and Disposition.
[31] J. Docherty,et al. Role of α1‐adrenoceptor subtypes in the effects of methylenedioxy methamphetamine (MDMA) on body temperature in the mouse , 2008, British journal of pharmacology.
[32] K. T. Wakabayashi,et al. A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse , 2008, Neuroscience.
[33] T. Monks,et al. Accumulation of Neurotoxic Thioether Metabolites of 3,4-(±)-Methylenedioxymethamphetamine in Rat Brain , 2008, Journal of Pharmacology and Experimental Therapeutics.
[34] J. Camarasa,et al. Memantine prevents MDMA-induced neurotoxicity. , 2008, Neurotoxicology.
[35] U. McCann,et al. Non-linear Pharmacokinetics of MDMA ( “ Ecstasy ” ) and its Major Metabolites in Squirrel Monkeys at Plasma Concentrations of MDMA that Develop After Typical Psychoactive Doses , 2008 .
[36] M. Meyer,et al. The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic MDMA and its Enantiomers , 2008 .
[37] M. Iwaki,et al. Differences in cytochrome P450 and nuclear receptor mRNA levels in liver and small intestines between SD and DA rats. , 2008, Drug metabolism and pharmacokinetics.
[38] H. Schiöth,et al. Extensive neuroadaptive changes in cortical gene-transcript expressions of the glutamate system in response to repeated intermittent MDMA administration in adolescent rats , 2008, BMC Neuroscience.
[39] R. Torre,et al. The relationship between core body temperature and 3,4-methylenedioxymethamphetamine metabolism in rats: implications for neurotoxicity , 2008, Psychopharmacology.
[40] D. Mash,et al. MDMA self‐administration in rats: acquisition, progressive ratio responding and serotonin transporter binding , 2007, The European journal of neuroscience.
[41] P. Guiry,et al. Comparative potencies of 3,4‐methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [3H]noradrenaline and [3H]5‐HT transport in mammalian cell lines , 2007, British journal of pharmacology.
[42] R. de la Torre,et al. Pharmacological Interaction between 3,4-Methylenedioxymethamphetamine (Ecstasy) and Paroxetine: Pharmacological Effects and Pharmacokinetics , 2007, Journal of Pharmacology and Experimental Therapeutics.
[43] M. Nader,et al. Ambient Temperature Effects on 3,4-Methylenedioxymethamphetamine-Induced Thermodysregulation and Pharmacokinetics in Male Monkeys , 2007, Drug Metabolism and Disposition.
[44] E. Fernandes,et al. Monoamine Oxidase-B Mediates Ecstasy-Induced Neurotoxic Effects to Adolescent Rat Brain Mitochondria , 2007, The Journal of Neuroscience.
[45] D. Pubill,et al. Methamphetamine and 3,4-methylenedioxymethamphetamine interact with central nicotinic receptors and induce their up-regulation. , 2007, Toxicology and applied pharmacology.
[46] Klaus-Peter Lesch,et al. 3,4-Methylenedioxymethamphetamine Self-Administration is Abolished in Serotonin Transporter Knockout Mice , 2007, Biological Psychiatry.
[47] L. Murri,et al. DNA fragmentation and oxidative stress in the hippocampal formation: a bridge between 3,4-methylenedioxymethamphetamine (ecstasy) intake and long-lasting behavioral alterations , 2007, Behavioural pharmacology.
[48] M. Delgado,et al. Mice with Decreased Cerebral Dopamine Function following a Neurotoxic Dose of MDMA (3,4-Methylenedioxymethamphetamine, “Ecstasy”) Exhibit Increased Ethanol Consumption and Preference , 2007, Journal of Pharmacology and Experimental Therapeutics.
[49] R. Rothman,et al. Restoration of 3,4-methylenedioxymethamphetamine-induced 5-HT depletion by the administration of l-5-hydroxytryptophan , 2007, Neuroscience.
[50] R. Hayes,et al. Calpain and caspase proteolytic markers co-localize with rat cortical neurons after exposure to methamphetamine and MDMA , 2007, Acta Neuropathologica.
[51] F. Carvalho,et al. Oxidation process of adrenaline in freshly isolated rat cardiomyocytes: formation of adrenochrome, quinoproteins, and GSH adduct. , 2007, Chemical research in toxicology.
[52] E. Fernandes,et al. Ecstasy induces apoptosis via 5-HT(2A)-receptor stimulation in cortical neurons. , 2007, Neurotoxicology.
[53] U. Dirnagl,et al. Neurotoxicity mechanisms of thioether ecstasy metabolites , 2007, Neuroscience.
[54] V. Vasiliou,et al. Neurotoxicity and Metabolism of the Catecholamine-Derived 3,4-Dihydroxyphenylacetaldehyde and 3,4-Dihydroxyphenylglycolaldehyde: The Role of Aldehyde Dehydrogenase , 2007, Pharmacological Reviews.
[55] Maarten Koeter,et al. Cognition in novice ecstasy users with minimal exposure to other drugs: a prospective cohort study. , 2007, Archives of general psychiatry.
[56] N. Ramsey,et al. Incidental use of ecstasy: no evidence for harmful effects on cognitive brain function in a prospective fMRI study , 2007, Psychopharmacology.
[57] M. Palkovits,et al. Single dose of MDMA causes extensive decrement of serotoninergic fibre density without blockage of the fast axonal transport in Dark Agouti rat brain and spinal cord , 2007, Neuropathology and applied neurobiology.
[58] B. Yamamoto,et al. Prior Exposure to Chronic Stress and MDMA Potentiates Mesoaccumbens Dopamine Release Mediated by the 5-HT1B Receptor , 2007, Neuropsychopharmacology.
[59] A. Urios,et al. Bacterial plate assays and electrochemical methods: an efficient tandem for evaluating the ability of catechol-thioether metabolites of MDMA ("ecstasy") to induce toxic effects through redox-cycling. , 2007, Chemical research in toxicology.
[60] C. Lay,et al. Impact of Ambient Temperature on Hyperthermia Induced by (±)3,4-Methylenedioxymethamphetamine in Rhesus Macaques , 2007, Neuropsychopharmacology.
[61] A. Parrott. The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): an evidence-based review , 2007, Psychopharmacology.
[62] F. Oesch,et al. CYP2D6 increases toxicity of the designer drug 4-methylthioamphetamine (4-MTA). , 2007, Toxicology.
[63] L. Coolen,et al. The effect of amphetamine analogs on cleaved microtubule-associated protein-tau formation in the rat brain , 2007, Neuroscience.
[64] J. O'Callaghan,et al. The role of temperature, stress, and other factors in the neurotoxicity of the substituted amphetamines 3,4-methylenedioxymethamphetamine and fenfluramine , 1995, Molecular Neurobiology.
[65] E. Fernandes,et al. Synthesis and cyclic voltammetry studies of 3,4-methylenedioxymethamphetamine (MDMA) human metabolites , 2007 .
[66] L. Johnston,et al. Monitoring the Future national survey results on drug use, 1975-2017: Volume II, college students and adults ages 19-55 , 2008 .
[67] U. Dirnagl,et al. Ecstasy-induced cell death in cortical neuronal cultures is serotonin 2A-receptor-dependent and potentiated under hyperthermia , 2006, Neuroscience.
[68] Jie Yuan,et al. Loss of Serotonin Transporter Protein after MDMA and Other Ring-Substituted Amphetamines , 2006, Neuropsychopharmacology.
[69] F. Oesch,et al. Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine (‘Ecstasy’) cytotoxicity , 2006, Pharmacogenetics and genomics.
[70] M. Colado,et al. Binge ethanol administration enhances the MDMA-induced long-term 5-HT neurotoxicity in rat brain , 2006, Psychopharmacology.
[71] M. Tancer,et al. The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans , 2006, Psychopharmacology.
[72] C. Lay,et al. Effects of (±)3,4-methylenedioxymethamphetamine, (±)3,4-methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques , 2006, Neuroscience.
[73] Allison G. Dempsey,et al. Interaction of Amphetamines and Related Compounds at the Vesicular Monoamine Transporter , 2006, Journal of Pharmacology and Experimental Therapeutics.
[74] J. Canales,et al. Binge administration of 3,4-methylenedioxymethamphetamine (“ecstasy”) impairs the survival of neural precursors in adult rat dentate gyrus , 2006, Neuropharmacology.
[75] Q. D. Walker,et al. Sex differences in the neurochemical and functional effects of MDMA in Sprague–Dawley rats , 2006, Psychopharmacology.
[76] R. Freudenmann,et al. The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. , 2006, Addiction.
[77] B. Sahakian,et al. The effect of polymorphism at the serotonin transporter gene on decision-making, memory and executive function in ecstasy users and controls , 2006, Psychopharmacology.
[78] F. Fornai,et al. MDMA Induces Caspase‐3 Activation in the Limbic System but not in Striatum , 2006, Annals of the New York Academy of Sciences.
[79] C. Adori,et al. Damage of serotonergic axons and immunolocalization of Hsp27, Hsp72, and Hsp90 molecular chaperones after a single dose of MDMA administration in Dark Agouti rat: Temporal, spatial, and cellular patterns , 2006, The Journal of comparative neurology.
[80] J. Koprich,et al. MDMA administration to pregnant Sprague-Dawley rats results in its passage to the fetal compartment. , 2006, Neurotoxicology and teratology.
[81] V. Sánchez,et al. MDMA‐induced neurotoxicity: long‐term effects on 5‐HT biosynthesis and the influence of ambient temperature , 2006, British journal of pharmacology.
[82] I. Singh,et al. Pharmacological strategies for the regulation of inducible nitric oxide synthase: Neurodegenerative versus neuroprotective mechanisms , 2006, Neurochemistry International.
[83] R. Rogers,et al. Elevated Impulsivity and Impaired Decision-Making in Abstinent Ecstasy (MDMA) Users Compared to Polydrug and Drug-Naïve Controls , 2006, Neuropsychopharmacology.
[84] C. Vorhees,et al. 3,4-Methylenedioxymethamphetamine in Adult Rats Produces Deficits in Path Integration and Spatial Reference Memory , 2006, Biological Psychiatry.
[85] J A Henry,et al. Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. , 2006, British journal of anaesthesia.
[86] C. Lay,et al. Hyperthermia induced by 3,4-methylenedioxymethamphetamine in unrestrained rhesus monkeys. , 2006, Drug and alcohol dependence.
[87] F. Jessen,et al. Memory deficits in abstinent MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction , 2006, Journal of psychopharmacology.
[88] K. Aitchison,et al. Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population , 2006, Journal of psychopharmacology.
[89] A. Hazell,et al. Excitotoxic mechanisms and the role of astrocytic glutamate transporters in traumatic brain injury , 2006, Neurochemistry International.
[90] J. Docherty,et al. Effects of MDMA, MDA and MDEA on blood pressure, heart rate, locomotor activity and body temperature in the rat involve α‐adrenoceptors , 2006, British journal of pharmacology.
[91] Michael H. Baumann,et al. 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings , 2006, Psychopharmacology.
[92] C. Vorhees,et al. Neonatal 3,4-methylenedioxymethamphetamine (MDMA) exposure alters neuronal protein kinase A activity, serotonin and dopamine content, and [35S]GTPγS binding in adult rats , 2006, Brain Research.
[93] H. Gu,et al. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs , 2006, BMC pharmacology.
[94] R. Buchert,et al. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective , 2006, Journal of psychopharmacology.
[95] C. Marsden,et al. Ecstasy: Are animal data consistent between species and can they translate to humans? , 2006, Journal of psychopharmacology.
[96] W. van den Brink,et al. Ecstasy use and self-reported depression, impulsivity, and sensation seeking: a prospective cohort study , 2006, Journal of psychopharmacology.
[97] K. Kitaichi,et al. Methamphetamine-induced Dopaminergic Neurotoxicity Is Regulated by Quinone Formation-related Molecules Materials and Methods , 2022 .
[98] F. Wan,et al. Effects of α-phenyl-N-tert-butyl nitrone and N-acetylcysteine on hydroxyl radical formation and dopamine depletion in the rat striatum produced by d-amphetamine , 2006, European Neuropsychopharmacology.
[99] U. McCann,et al. Pharmacokinetic Profile of Single and Repeated Oral Doses of MDMA in Squirrel Monkeys: Relationship to Lasting Effects on Brain Serotonin Neurons , 2006, Neuropsychopharmacology.
[100] Jason M. White,et al. Plasma Drug Concentrations and Physiological Measures in ‘Dance Party’ Participants , 2006, Neuropsychopharmacology.
[101] B. O’Neill,et al. Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA (“Ecstasy”) and MDA (“Love”) , 2006, Neuropharmacology.
[102] B. Yamamoto,et al. L-Tyrosine Contributes to (+)-3,4-Methylenedioxymethamphetamine-Induced Serotonin Depletions , 2006, The Journal of Neuroscience.
[103] F. Carvalho,et al. Neurotoxicity of Ecstasy Metabolites in Rat Cortical Neurons, and Influence of Hyperthermia , 2006, Journal of Pharmacology and Experimental Therapeutics.
[104] 宮崎 育子. Methamphetamine-induced dopaminergic neurotoxicity is regulated by quinone formation-related molecules , 2006 .
[105] Syed F. Ali,et al. Role of nitrergic system in behavioral and neurotoxic effects of amphetamine analogs. , 2006, Pharmacology & therapeutics.
[106] V. Sánchez,et al. 3,4-Methylenedioxymethamphetamine increases pro-interleukin-1β production and caspase-1 protease activity in frontal cortex, but not in hypothalamus, of Dark Agouti rats: Role of interleukin-1β in neurotoxicity , 2005, Neuroscience.
[107] J. Foster,et al. Psychoactive Substrates Stimulate Dopamine Transporter Phosphorylation and Down-regulation by Cocaine-sensitive and Protein Kinase C-dependent Mechanisms* , 2005, Journal of Biological Chemistry.
[108] B. Goñi-Allo,et al. Administration of SCH 23390 into the Medial Prefrontal Cortex Blocks the Expression of MDMA-Induced Behavioral Sensitization in Rats: An Effect Mediated by 5-HT2C Receptor Stimulation and not by D1 Receptor Blockade , 2005, Neuropsychopharmacology.
[109] I. Kunz. Acute medical problems due to Ecstasy use , 2005, Swiss Medical Weekly.
[110] M. Liechti,et al. Acute medical problems due to Ecstasy use. Case-series of emergency department visits. , 2005, Swiss medical weekly.
[111] M. Tancer,et al. Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans , 2005, Psychopharmacology.
[112] M. Morales,et al. (±)-3,4-Methylenedioxymethamphetamine Administration to Rats Does Not Decrease Levels of the Serotonin Transporter Protein or Alter Its Distribution between Endosomes and the Plasma Membrane , 2005, Journal of Pharmacology and Experimental Therapeutics.
[113] J. Docherty,et al. Role of α2A‐adrenoceptors in the effects of MDMA on body temperature in the mouse , 2005, British journal of pharmacology.
[114] M. Colado,et al. Studies on the effect of MDMA (‘ecstasy’) on the body temperature of rats housed at different ambient room temperatures , 2005, British journal of pharmacology.
[115] Zsolt Szabo,et al. Quantitative PET Studies of the Serotonin Transporter in MDMA Users and Controls Using [11C]McN5652 and [11C]DASB , 2005, Neuropsychopharmacology.
[116] C. Vorhees,et al. Learning and memory after neonatal exposure to 3,4‐methylenedioxymethamphetamine (ecstasy) in rats: Interaction with exposure in adulthood , 2005, Synapse.
[117] B. Piper,et al. Repeated MDMA ("Ecstasy") exposure in adolescent male rats alters temperature regulation, spontaneous motor activity, attention, and serotonin transporter binding. , 2005, Developmental psychobiology.
[118] R. de la Torre,et al. MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers , 2005, European Journal of Clinical Pharmacology.
[119] C. Riegert,et al. MDMA (ecstasy) effects in pubescent rats: Males are more sensitive than females , 2005, Pharmacology Biochemistry and Behavior.
[120] K. Lesch,et al. Pharmacogenetics of the serotonin transporter , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[121] V. Sánchez,et al. Elevation of Ambient Room Temperature has Differential Effects on MDMA-Induced 5-HT and Dopamine Release in Striatum and Nucleus Accumbens of Rats , 2005, Neuropsychopharmacology.
[122] J. Woods,et al. Serotonin synthesis inhibition reveals distinct mechanisms of action for MDMA and its enantiomers in the mouse , 2005, Psychopharmacology.
[123] I. McGregor,et al. Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[124] D. Goldstein,et al. Carvedilol reverses hyperthermia and attenuates rhabdomyolysis induced by 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) in an animal model* , 2005, Critical care medicine.
[125] B. Sessa. Can psychedelics have a role in psychiatry once again? , 2005, The British journal of psychiatry : the journal of mental science.
[126] R. Blakely,et al. Evidence for Biphasic Effects of Protein Kinase C on Serotonin Transporter Function, Endocytosis, and Phosphorylation , 2005, Molecular Pharmacology.
[127] Sheng Li,et al. Identification of Stereoselective Transporters for S-Nitroso-L-cysteine , 2005, Journal of Biological Chemistry.
[128] M. Nader,et al. A comparison of the reinforcing efficacy of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") with cocaine in rhesus monkeys. , 2005, Drug and alcohol dependence.
[129] D. Matsuzawa,et al. A functional glutathione S‐transferase P1 gene polymorphism is associated with methamphetamine‐induced psychosis in Japanese population , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[130] R. de la Torre,et al. Serotonergic Neurotoxic Metabolites of Ecstasy Identified in Rat Brain , 2005, Journal of Pharmacology and Experimental Therapeutics.
[131] C. Vorhees,et al. 3,4-Methylenedioxymethamphetamine administration on postnatal day 11 in rats increases pituitary–adrenal output and reduces striatal and hippocampal serotonin without altering SERT activity , 2005, Brain Research.
[132] B. Blough,et al. N-Substituted Piperazines Abused by Humans Mimic the Molecular Mechanism of 3,4-Methylenedioxymethamphetamine (MDMA, or ‘Ecstasy’) , 2005, Neuropsychopharmacology.
[133] Jonathan A Javitch,et al. Amphetamine induces dopamine efflux through a dopamine transporter channel. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[134] B. Sahakian,et al. Association of a functional polymorphism in the serotonin transporter gene with abnormal emotional processing in ecstasy users. , 2005, The American journal of psychiatry.
[135] D. Guilloteau,et al. Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) exposure induces long-term alterations in the dopaminergic and serotonergic functions in the rat. , 2005, Brain research. Developmental brain research.
[136] A. S. Darvesh,et al. Evidence for the Involvement of Nitric Oxide in 3,4-Methylenedioxymethamphetamine-Induced Serotonin Depletion in the Rat Brain , 2005, Journal of Pharmacology and Experimental Therapeutics.
[137] J. Morton,et al. Ecstasy: pharmacology and neurotoxicity. , 2005, Current opinion in pharmacology.
[138] V. Sánchez,et al. A comparative study on the acute and long‐term effects of MDMA and 3,4‐dihydroxymethamphetamine (HHMA) on brain monoamine levels after i.p. or striatal administration in mice , 2005, British journal of pharmacology.
[139] D. Nichols,et al. Inhibition of MAO-B protects against MDMA-induced neurotoxicity in the striatum , 1995, Psychopharmacology.
[140] M. Farré,et al. Contribution of Cytochrome P450 2D6 to 3,4-Methylenedioxymethamphetamine Disposition in Humans , 2005, Clinical pharmacokinetics.
[141] G. Gudelsky. Effect of ascorbate and cysteine on the 3,4-methylenedioxymethamphetamine-induced depletion of brain serotonin , 2005, Journal of Neural Transmission.
[142] K. Heekeren,et al. Memory-related hippocampal dysfunction in poly-drug ecstasy (3,4-methylenedioxymethamphetamine) users , 2005, Psychopharmacology.
[143] J. Kellerth,et al. Sensory neuroprotection, mitochondrial preservation, and therapeutic potential of n-acetyl-cysteine after nerve injury , 2004, Neuroscience.
[144] K. Noguchi,et al. The neurotoxic effects of 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine on serotonin, dopamine, and GABA-ergic terminals: an in-vitro autoradiographic study in rats. , 2004, Neurotoxicology.
[145] B. Piper,et al. Memory deficit and reduced anxiety in young adult rats given repeated intermittent MDMA treatment during the periadolescent period , 2004, Pharmacology Biochemistry and Behavior.
[146] F. Carvalho,et al. Metabolism of the designer drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in mice, after acute administration. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[147] F. Carvalho,et al. Leucoisoprenochrome-o-semiquinone formation in freshly isolated adult rat cardiomyocytes. , 2004, Chemical research in toxicology.
[148] C. Vorhees,et al. Absorption and clearance of +/-3,4-methylenedioxymethamphetamine from the plasma of neonatal rats. , 2004, Neurotoxicology and teratology.
[149] G. Tucker,et al. MECHANISM-BASED INACTIVATION OF CYP2D6 BY METHYLENEDIOXYMETHAMPHETAMINE , 2004, Drug Metabolism and Disposition.
[150] B. Yamamoto,et al. Serotonin–GABA interactions modulate MDMA‐induced mesolimbic dopamine release , 2004, Journal of neurochemistry.
[151] G K L Butler,et al. Impulsivity, risk taking and recreational 'ecstasy' (MDMA) use. , 2004, Drug and alcohol dependence.
[152] R. de la Torre,et al. Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. , 2004, Trends in pharmacological sciences.
[153] G. Lazzeri,et al. Effects of Repeated Low Doses of MDMA on EEG Activity and Fluoro‐Jade B Histochemistry , 2004, Annals of the New York Academy of Sciences.
[154] Syed F. Ali,et al. Differential Response of nNOS Knockout Mice to MDMA (“Ecstasy”)‐ and Methamphetamine‐Induced Psychomotor Sensitization and Neurotoxicity , 2004, Annals of the New York Academy of Sciences.
[155] T. Monks,et al. Thioether Metabolites of 3,4-Methylenedioxyamphetamine and 3,4-Methylenedioxymethamphetamine Inhibit Human Serotonin Transporter (hSERT) Function and Simultaneously Stimulate Dopamine Uptake into hSERT-Expressing SK-N-MC Cells , 2004, Journal of Pharmacology and Experimental Therapeutics.
[156] R. Rothman,et al. 3,4‐methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein , 2004, Synapse.
[157] D. Kuhn,et al. Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines , 2004, Neuroscience Letters.
[158] K. Heekeren,et al. Neural mechanisms of working memory in ecstasy (MDMA) users who continue or discontinue ecstasy and amphetamine use: Evidence from an 18-month longitudinal functional magnetic resonance imaging study , 2004, Biological Psychiatry.
[159] V. Sánchez,et al. Effect of Repeated (‘Binge’) Dosing of MDMA to Rats Housed at Normal and High Temperature on Neurotoxicdamage to Cerebral 5-Ht and Dopamine Neurones , 2004, Journal of psychopharmacology.
[160] R. de la Torre,et al. Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[161] E. Fernandes,et al. The toxicity of N-methyl-α-methyldopamine to freshly isolated rat hepatocytes is prevented by ascorbic acid and N-acetylcysteine , 2004 .
[162] Kenneth M. Johnson,et al. Neurotoxic effects of MDMA (“ecstasy”) administration to neonatal rats , 2004, International Journal of Developmental Neuroscience.
[163] E. Nalivaiko,et al. Spinal 5-HT2A receptors regulate cutaneous sympathetic vasomotor outflow in rabbits and rats; relevance for cutaneous vasoconstriction elicited by MDMA (3,4-methylenedioxymethamphetamine, “Ecstasy”) and its reversal by clozapine , 2004, Brain Research.
[164] Ralph Buchert,et al. A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters. , 2004, The American journal of psychiatry.
[165] P. Renshaw,et al. Functional MRI study of working memory in MDMA users , 2004, Psychopharmacology.
[166] D. Rusyniak,et al. Attenuation of 3,4‐methylenedioxymethamphetamine (MDMA, Ecstasy)‐induced rhabdomyolysis with α1‐ plus β3‐adrenoreceptor antagonists , 2004 .
[167] V. Sánchez,et al. 3,4‐Methylenedioxymethamphetamine increases interleukin‐1β levels and activates microglia in rat brain: studies on the relationship with acute hyperthermia and 5‐HT depletion , 2004, Journal of neurochemistry.
[168] E. Check. Psychedelic drugs: The ups and downs of ecstasy , 2004, Nature.
[169] E. Fernandes,et al. Metabolism is required for the expression of ecstasy-induced cardiotoxicity in vitro. , 2004, Chemical research in toxicology.
[170] M. Pallàs,et al. Neurotoxicity of amphetamine derivatives is mediated by caspase pathway activation in rat cerebellar granule cells. , 2004, Toxicology and applied pharmacology.
[171] M. Farré,et al. Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics , 2004, Psychopharmacology.
[172] T. Connor. Methylenedioxymethamphetamine (MDMA, ‘Ecstasy’): a stressor on the immune system , 2004, Immunology.
[173] T. Monks,et al. The Role of Metabolism in 3,4-(±)-Methylenedioxyamphetamine and 3,4-(±)-Methylenedioxymethamphetamine (Ecstasy) toxicity , 2004, Therapeutic drug monitoring.
[174] H. Sumnall,et al. The effects of MDMA pretreatment on the behavioural effects of other drugs of abuse in the rat elevated plus-maze test , 2004, Pharmacology Biochemistry and Behavior.
[175] Magnus Ingelman-Sundberg,et al. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. , 2004, Trends in pharmacological sciences.
[176] G. Ricaurte,et al. Behavioral and Neurochemical Consequences of Long-Term Intravenous Self-Administration of MDMA and Its Enantiomers by Rhesus Monkeys , 2004, Neuropsychopharmacology.
[177] R. Schwarting,et al. Acute and long-term consequences of single MDMA administration in relation to individual anxiety levels in the rat , 2004, Behavioural Brain Research.
[178] K. Fone,et al. Decreased social behaviour following 3,4-methylenedioxymethamphetamine (MDMA) is accompanied by changes in 5-HT2A receptor responsivity , 2004, Neuropharmacology.
[179] R. Glennon,et al. Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis , 1989, Psychopharmacology.
[180] M. Farré,et al. Clinical Pharmacokinetics of Amfetamine and Related Substances , 2004, Clinical pharmacokinetics.
[181] T. Nagatsu. Progress in monoamine oxidase (MAO) research in relation to genetic engineering. , 2004, Neurotoxicology.
[182] F. Biagioni,et al. DNA damage and ubiquitinated neuronal inclusions in the substantia nigra and striatum of mice following MDMA (ecstasy) , 2004, Psychopharmacology.
[183] P. Skudlarski,et al. Preliminary evidence of hippocampal dysfunction in adolescent MDMA (“ecstasy”) users: possible relationship to neurotoxic effects , 2004, Psychopharmacology.
[184] M. Colado,et al. Hyperthermic and neurotoxic effect of 3,4-methylenedioxymethamphetamine (MDMA) in guinea pigs , 2004, Psychopharmacology.
[185] R. Dafters,et al. Contribution of cannabis and MDMA ("ecstasy") to cognitive changes in long-term polydrug users , 2004, Psychopharmacology.
[186] A. Parrott. Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity , 2004, Psychopharmacology.
[187] J. O'Callaghan,et al. Brain concentrations of d-MDMA are increased after stress , 2004, Psychopharmacology.
[188] J. Koprich,et al. Neonatal 3,4-methylenedioxymethamphetamine (ecstasy) alters dopamine and serotonin neurochemistry and increases brain-derived neurotrophic factor in the forebrain and brainstem of the rat. , 2003, Brain research. Developmental brain research.
[189] P. Renshaw,et al. Reduced cortical gray matter density in human MDMA (Ecstasy) users: a voxel-based morphometry study. , 2003, Drug and alcohol dependence.
[190] G. Wakonigg,et al. Methylenedioxymethamphetamine (MDMA, ‘Ecstasy‘) Serves as a Robust Positive Reinforcer in a Rat Runway Procedure , 2003, Pharmacology.
[191] T. Finkel,et al. Pharmacology: Uncoupling the agony from ecstasy , 2003, Nature.
[192] F. Wappler,et al. Induction of Malignant Hyperthermia in Susceptible Swine by 3,4-Methylenedioxymethamphetamine (“Ecstasy”) , 2003, Anesthesiology.
[193] G. Hanson,et al. Impact of psychostimulants on vesicular monoamine transporter function. , 2003, European journal of pharmacology.
[194] R. Rothman,et al. Monoamine transporters and psychostimulant drugs. , 2003, European journal of pharmacology.
[195] M. Tancer,et al. Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. , 2003, Drug and alcohol dependence.
[196] C. Marsden,et al. Synthesis, in vitro formation, and behavioural effects of glutathione regioisomers of alpha-methyldopamine with relevance to MDA and MDMA (ecstasy) , 2003, Brain Research.
[197] G. Lazzeri,et al. Amphetamines induce ubiquitin-positive inclusions within striatal cells , 2003, Neurological Sciences.
[198] J. Kordower,et al. Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) alters exploratory behavior, reduces monoamine metabolism, and increases forebrain tyrosine hydroxylase fiber density of juvenile rats. , 2003, Neurotoxicology and teratology.
[199] C. Jurado,et al. Tissue concentrations of MDMA and its metabolite MDA in three fatal cases of overdose. , 2003, Forensic science international.
[200] E. Gouzoulis-Mayfrank,et al. Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[201] W. Blessing,et al. Clozapine Reverses Hyperthermia and Sympathetically Mediated Cutaneous Vasoconstriction Induced by 3,4-Methylenedioxymethamphetamine (Ecstasy) in Rabbits and Rats , 2003, The Journal of Neuroscience.
[202] Michael Leifheit,et al. Hippocampal serotonergic damage induced by MDMA (ecstasy): effects on spatial learning , 2003, Physiology & Behavior.
[203] L. Schmued. Demonstration and localization of neuronal degeneration in the rat forebrain following a single exposure to MDMA , 2003, Brain Research.
[204] John F. Young,et al. Plasma levels of parent compound and metabolites after doses of either d-fenfluramine or d-3,4-methylenedioxymethamphetamine (MDMA) that produce long-term serotonergic alterations. , 2003, Neurotoxicology.
[205] R. Rossaint,et al. [Hyperpyrexia and rhabdomyolysis after ecstasy (MDMA) intoxication]. , 2003, Der Anaesthesist.
[206] R. Rossaint,et al. Ausgeprägte Hyperthermie und Rhabdomyolyse nach Ecstasy (MDMA)-Intoxikation , 2003, Der Anaesthesist.
[207] D. Gittings,et al. Development, maintenance and temporal pattern of self-administration maintained by ecstasy (MDMA) in rats , 2003, Psychopharmacology.
[208] K. Bode-Greuel,et al. Additive neuroprotective effect of Ketanserin and Ipsapirone on the hippocampal damage after transient forebrain ischemia in the Mongolian gerbil , 2003, Neuroscience Letters.
[209] Mushfiquddin Khan,et al. N-Acetyl cysteine protects against injury in a rat model of focal cerebral ischemia , 2003, Brain Research.
[210] M. Egan,et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[211] W. Blessing,et al. 5-hydroxytryptamine2A receptors regulate sympathetic nerves constricting the cutaneous vascular bed in rabbits and rats , 2003, Neuroscience.
[212] M. Pallàs,et al. Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.
[213] H. Sumnall,et al. Altered states: the clinical effects of Ecstasy. , 2003, Pharmacology & therapeutics.
[214] M. Banks,et al. Hypothalamic-Pituitary-Thyroid Axis and Sympathetic Nervous System Involvement in Hyperthermia Induced by 3,4-Methylenedioxymethamphetamine (Ecstasy) , 2003, Journal of Pharmacology and Experimental Therapeutics.
[215] C. Meisel,et al. Implications of pharmacogenetics for individualizing drug treatment and for study design , 2003, Journal of Molecular Medicine.
[216] K. Fone,et al. Reduced social interaction following 3,4-methylenedioxymethamphetamine is not associated with enhanced 5-HT2C receptor responsivity , 2003, Neuropharmacology.
[217] J. Steketee,et al. Neurotransmitter systems of the medial prefrontal cortex: potential role in sensitization to psychostimulants , 2003, Brain Research Reviews.
[218] Ralph Buchert,et al. Long-term effects of "ecstasy" use on serotonin transporters of the brain investigated by PET. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[219] Karen L. Anderson,et al. Relevance of MDMA ("ecstasy")-induced neurotoxicity to long-lasting psychomotor stimulation in mice , 2003, Psychopharmacology.
[220] M. Carraway,et al. Postlipopolysaccharide oxidative damage of mitochondrial DNA. , 2003, American journal of respiratory and critical care medicine.
[221] Howard L McLeod,et al. Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.
[222] A. Daly,et al. Pharmacogenetics of the major polymorphic metabolizing enzymes , 2003, Fundamental & clinical pharmacology.
[223] T. Ullrich,et al. Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice , 2003, Psychopharmacology.
[224] L. King. The Misuse of Drugs Act , 2003 .
[225] F. Carvalho,et al. Synthesis and analysis of aminochromes by HPLC-photodiode array. Adrenochrome evaluation in rat blood. , 2003, Biomedical chromatography : BMC.
[226] Ulrich M. Zanger,et al. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.
[227] M. Eichelbaum,et al. V79 Chinese hamster cells genetically engineered for polymorphic cytochrome P450 2D6 and their predictive value for humans. , 2003, ALTEX.
[228] J. Miners,et al. Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. , 2002, Toxicology.
[229] H. J. Olverman,et al. Functional consequences of perinatal exposure to3,4‐methylenedioxymethamphetamine in rat brain , 2002, British journal of pharmacology.
[230] Liesbeth Reneman,et al. Validity of [123I]β‐CIT SPECT in detecting MDMA‐induced serotonergic neurotoxicity , 2002, Synapse.
[231] A. Kanthasamy,et al. Unilateral infusion of a dopamine transporter antisense into the substantia nigra protects against MDMA-induced serotonergic deficits in the ipsilateral striatum , 2002, Neuroscience.
[232] U. Brinkmann,et al. Modulation of steady‐state kinetics of digoxin by haplotypes of the P‐glycoprotein MDR1 gene , 2002, Clinical pharmacology and therapeutics.
[233] J. Navarro,et al. Acute and subchronic effects of MDMA (“ecstasy”) on anxiety in male mice tested in the elevated plus-maze , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[234] Xiang-Rong Jiang,et al. Inhibition of the alpha-ketoglutarate dehydrogenase and pyruvate dehydrogenase complexes by a putative aberrant metabolite of serotonin, tryptamine-4,5-dione. , 2002, Chemical research in toxicology.
[235] K. Varner,et al. Changes in cardiovascular responsiveness and cardiotoxicity elicited during binge administration of Ecstasy. , 2002, The Journal of pharmacology and experimental therapeutics.
[236] P. Morméde,et al. Influences of the corticotropic axis and sympathetic activity on neurochemical consequences of 3,4‐methylenedioxymethamphetamine (MDMA) administration in Fischer 344 rats , 2002, The European journal of neuroscience.
[237] E. Fernandes,et al. Role of metabolites in MDMA (ecstasy)-induced nephrotoxicity: an in vitro study using rat and human renal proximal tubular cells , 2002, Archives of Toxicology.
[238] A. Daly,et al. CYP2D6 deficiency, a factor in ecstasy related deaths? , 2002, British journal of clinical pharmacology.
[239] R. Tyndale,et al. Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. , 2002, Biochemical pharmacology.
[240] Syed F. Ali,et al. Serotonergic Neurotoxicity of MDMA (Ecstasy) in the Developing Rat Brain , 2002, Annals of the New York Academy of Sciences.
[241] D. Nichols,et al. An antisense oligonucleotide targeted at MAO-B attenuates rat striatal serotonergic neurotoxicity induced by MDMA , 2002, Pharmacology, Biochemistry and Behavior.
[242] F. Fornai,et al. Striatal Postsynaptic Ultrastructural Alterations Following Methylenedioxymethamphetamine Administration , 2002, Annals of the New York Academy of Sciences.
[243] B. Zhu. Catechol-O-Methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. , 2002, Current drug metabolism.
[244] F. Carvalho,et al. Cu2+-induced isoproterenol oxidation into isoprenochrome in adult rat calcium-tolerant cardiomyocytes. , 2002, Chemical research in toxicology.
[245] B. Sahakian,et al. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users , 2002, Psychopharmacology.
[246] T. Ullrich,et al. 3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement , 2002, Psychopharmacology.
[247] B. Halliwell,et al. 5‐S‐Cysteinyl‐conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase‐3 activity in neurons , 2002, Journal of neurochemistry.
[248] R. Doblin. A Clinical Plan for MDMA (Ecstasy) in the Treatment of Posttraumatic Stress Disorder (PTSD): Partnering with the FDA , 2002, Journal of psychoactive drugs.
[249] S. Kish. How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? , 2002, Pharmacology Biochemistry and Behavior.
[250] V. Curran,et al. Sub-acute effects of MDMA (±3,4-methylenedioxymethamphetamine, "ecstasy") on mood: evidence of gender differences , 2002, Psychopharmacology.
[251] U. McCann,et al. Effect of depleting vesicular and cytoplasmic dopamine on methylenedioxymethamphetamine neurotoxicity , 2002, Journal of neurochemistry.
[252] F. Carvalho,et al. Effect of 3,4-methylenedioxymethamphetamine ("ecstasy") on body temperature and liver antioxidant status in mice: influence of ambient temperature , 2002, Archives of Toxicology.
[253] L. Reneman,et al. The Acute and Chronic Effects of MDMA (“Ecstasy”) on Cortical 5-HT2A Receptors in Rat and Human Brain , 2002, Neuropsychopharmacology.
[254] M. Carraway,et al. Rapid mtDNA deletion by oxidants in rat liver mitochondria after hemin exposure. , 2002, Free radical biology & medicine.
[255] F. Belpaire,et al. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. , 2002, Current drug metabolism.
[256] M. Colado,et al. The pharmacology of the acute hyperthermic response that follows administration of 3,4‐methylenedioxymethamphetamine (MDMA, ‘ecstasy’) to rats , 2002, British journal of pharmacology.
[257] L. Johnston,et al. Monitoring the Future national survey results on drug use, 1975-2017: Volume I, secondary school students , 2005 .
[258] J. Swettenham,et al. Long-term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity , 2002, Psychopharmacology.
[259] M. Colado,et al. Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA (‘ecstasy’) on the 5-HT and dopamine concentrations in mouse brain , 2001, Neuropharmacology.
[260] R. Weinshilboum,et al. Human sulfotransferase SULT1C1 pharmacogenetics: gene resequencing and functional genomic studies. , 2001, Pharmacogenetics.
[261] V. Sánchez,et al. A study of the mechanisms involved in the neurotoxic action of 3,4‐methylenedioxymethamphetamine (MDMA, ‘ecstasy’) on dopamine neurones in mouse brain , 2001, British journal of pharmacology.
[262] Liesbeth Reneman,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[263] Efrain C Azmitia,et al. Modern views on an ancient chemical: serotonin effects on cell proliferation, maturation, and apoptosis , 2001, Brain Research Bulletin.
[264] Y. Sugimoto,et al. Involvement of serotonergic and dopaminergic mechanisms in hyperthermia induced by a serotonin-releasing drug, p-chloroamphetamine in mice. , 2001, European journal of pharmacology.
[265] R. de la Torre,et al. Effects of repeated doses of MDMA ("ecstasy") on cell-mediated immune response in humans. , 2001, Life sciences.
[266] C. Guillemette,et al. Tobacco carcinogen-detoxifying enzyme UGT1A7 and its association with orolaryngeal cancer risk. , 2001, Journal of the National Cancer Institute.
[267] G. Dryhurst,et al. A putative metabolite of serotonin, tryptamine-4,5-dione, is an irreversible inhibitor of tryptophan hydroxylase: possible relevance to the serotonergic neurotoxicity of methamphetamine. , 2001, Chemical research in toxicology.
[268] R. de la Torre,et al. 3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. , 2001, Chemical research in toxicology.
[269] V. Sánchez,et al. The mechanisms involved in the long‐lasting neuroprotective effect of fluoxetine against MDMA (‘ecstasy’)‐induced degeneration of 5‐HT nerve endings in rat brain , 2001, British journal of pharmacology.
[270] R. Tyndale,et al. Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. , 2001, Pharmacogenetics.
[271] A. Pentney. An Exploration of the History and Controversies Surrounding MDMA and MDA , 2001, Journal of psychoactive drugs.
[272] M. Colado,et al. A neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) to rats results in a long term defect in thermoregulation , 2001, Psychopharmacology.
[273] N. Nishiyama,et al. Phospholipase A2 mediates ischemic injury in the hippocampus: a regional difference of neuronal vulnerability , 2001, The European journal of neuroscience.
[274] P. Anzenbacher,et al. Cytochromes P450 and metabolism of xenobiotics , 2001, Cellular and Molecular Life Sciences CMLS.
[275] Charles V. Vorhees,et al. 3,4-Methylenedioxymethamphetamine (Ecstasy)-Induced Learning and Memory Impairments Depend on the Age of Exposure during Early Development , 2001, The Journal of Neuroscience.
[276] B. Yamamoto,et al. Ascorbic acid prevents 3,4‐methylenedioxymethamphetamine (MDMA)‐induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5‐HT , 2001, Synapse.
[277] Kevin S. Chen,et al. Biochemical effects of the monoamine neurotoxins DSP‐4 and MDMA in specific brain regions of MAO‐B‐deficient mice , 2001, Synapse.
[278] V. Sánchez,et al. 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose , 2001, Psychopharmacology.
[279] F. Vollenweider,et al. No Difference in Brain Activation During Cognitive Performance Between Ecstasy (3,4-Methylenedioxymethamphetamine) Users and Control Subjects: A [H215O]-Positron Emission Tomography Study , 2001, Journal of clinical psychopharmacology.
[280] F. Carvalho,et al. Is hyperthermia the triggering factor for hepatotoxicity induced by 3,4-methylenedioxymethamphetamine (ecstasy)? An in vitro study using freshly isolated mouse hepatocytes , 2001, Archives of Toxicology.
[281] K. Rice,et al. Amphetamine‐type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin , 2001, Synapse.
[282] J. Robinson,et al. Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence? , 2001, Psychopharmacology.
[283] Patrick M. O'Malley,et al. Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings, 2004. , 2003 .
[284] A. Syvänen,et al. Pharmacogenetics of catechol‐O‐methyltransferase: Frequency of low activity allele in a Ghanaian population , 2000, Human mutation.
[285] M Schwab,et al. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. , 2000, Pharmacogenetics.
[286] F. Vollenweider,et al. Psychological and Physiological Effects of MDMA (“Ecstasy”) after Pretreatment with the 5-HT2 Antagonist Ketanserin in Healthy Humans , 2000, Neuropsychopharmacology.
[287] B. Lasheras,et al. 2‐Deoxy‐D‐Glucose Prevents and Nicotinamide Potentiates 3,4‐Methylenedioxymethamphetamine‐Induced Serotonin Neurotoxicity , 2000, Journal of neurochemistry.
[288] Diane B Miller,et al. Restraint as a stressor in mice: Against the dopaminergic neurotoxicity of d-MDMA, low body weight mitigates restraint-induced hypothermia and consequent neuroprotection , 2000, Brain Research.
[289] J. Kelly,et al. Methylenedioxymethamphetamine (MDMA; Ecstasy) suppresses IL-1β and TNF-α secretion following an in vivo lipopolysaccharide challenge , 2000 .
[290] S. Kish,et al. Brief Communications Expedited Publication Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user , 2000 .
[291] H. Pope,et al. MDMA ("Ecstasy") abuse and high-risk sexual behaviors among 169 gay and bisexual men. , 2000, The American journal of psychiatry.
[292] P. O'cain,et al. Cardiovascular and sympathetic responses and reflex changes elicited by MDMA , 2000, Physiology & Behavior.
[293] J. Rodgers,et al. Cognitive performance amongst recreational users of "ecstasy , 2000, Psychopharmacology.
[294] K. Kreth,et al. Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs. , 2000, Biochemical pharmacology.
[295] U. McCann,et al. (±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Studies in Animals , 2000, Neuropsychobiology.
[296] F. Vollenweider,et al. The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3, 4-methylenedioxymethamphetamine (‘Ecstasy’) in healthy volunteers , 2000, Journal of psychopharmacology.
[297] S. Pandey,et al. Cellular localization of serotonin2A (5HT2A) receptors in the rat brain , 2000, Brain Research Bulletin.
[298] C. Humpel,et al. MDMA (‘ecstasy’) enhances basal acetylcholine release in brain slices of the rat striatum , 2000, The European journal of neuroscience.
[299] F. Peters,et al. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy'). , 2000, Toxicology letters.
[300] P. McGuire. Long term psychiatric and cognitive effects of MDMA use. , 2000, Toxicology letters.
[301] R. de la Torre,et al. Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. , 2000, British journal of clinical pharmacology.
[302] W. van den Brink,et al. Memory disturbances in ”Ecstasy” users are correlated with an altered brain serotonin neurotransmission , 2000, Psychopharmacology.
[303] J. Kelly,et al. Methylenedioxymethamphetamine (MDMA; Ecstasy) suppresses IL-1beta and TNF-alpha secretion following an in vivo lipopolysaccharide challenge. , 2000, Life sciences.
[304] K. Nagata,et al. Pharmacogenetics of sulfotransferase. , 2000, Annual review of pharmacology and toxicology.
[305] B. Yamamoto,et al. Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine. , 1999, European journal of pharmacology.
[306] E. Connolly,et al. MDMA toxicity presenting with severe hyperpyrexia: a case report. , 1999, Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine.
[307] M. Ramírez,et al. Alpha-lipoic acid prevents 3,4-methylenedioxy-methamphetamine (MDMA)-induced neurotoxicity. , 1999, Neuroreport.
[308] T. Monks,et al. Glutathione and N-acetylcysteine conjugates of alpha-methyldopamine produce serotonergic neurotoxicity: possible role in methylenedioxyamphetamine-mediated neurotoxicity. , 1999, Chemical research in toxicology.
[309] J. Docherty,et al. Investigation of the prejunctional α2‐adrenoceptor mediated actions of MDMA in rat atrium and vas deferens , 1999 .
[310] M. Shankaran,et al. A neurotoxic regimen of MDMA suppresses behavioral, thermal and neurochemical responses to subsequent MDMA administration , 1999, Psychopharmacology.
[311] L. Vanderschuren,et al. A Single Exposure to Amphetamine Is Sufficient to Induce Long-Term Behavioral, Neuroendocrine, and Neurochemical Sensitization in Rats , 1999, The Journal of Neuroscience.
[312] M. Relling,et al. Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.
[313] S. Gore. Fatal uncertainty: death-rate from use of ecstasy or heroin , 1999, The Lancet.
[314] M. Ingelman-Sundberg,et al. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. , 1999, Trends in pharmacological sciences.
[315] H. Meltzer. The Role of Serotonin in Antipsychotic Drug Action , 1999, Neuropsychopharmacology.
[316] R. Blakely,et al. Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. , 1999, Science.
[317] Klaus P. Ebmeier,et al. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (‘ecstasy’) users , 1999, British Journal of Psychiatry.
[318] M. Delaforge,et al. Inhibitory metabolite complex formation of methylenedioxymethamphetamine with rat and human cytochrome P450. Particular involvement of CYP 2D. , 1999, Environmental toxicology and pharmacology.
[319] P. Milligan,et al. Stereospecific analysis and enantiomeric disposition of 3, 4-methylenedioxymethamphetamine (Ecstasy) in humans. , 1999, Clinical chemistry.
[320] G. Ricaurte,et al. Altered Serotonin Innervation Patterns in the Forebrain of Monkeys Treated with (±)3,4-Methylenedioxymethamphetamine Seven Years Previously: Factors Influencing Abnormal Recovery , 1999, The Journal of Neuroscience.
[321] B. Yamamoto,et al. Mazindol Attenuates the 3,4‐Methylenedioxymethamphetamine‐Induced Formation of Hydroxyl Radicals and Long‐Term Depletion of Serotonin in the Striatum , 1999, Journal of neurochemistry.
[322] J. Schlegel,et al. Amphetamines induce apoptosis and regulation of bcl‐x splice variants in neocortical neurons , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[323] D. Thomason,et al. Impact of genetic polymorphisms of the β2‐adrenergic receptor on albuterol bronchodilator pharmacodynamics , 1999, Clinical pharmacology and therapeutics.
[324] S. Butcher,et al. Behavioural analysis of the acute and chronic effects of MDMA treatment in the rat , 1999, Psychopharmacology.
[325] G. Dryhurst,et al. Tryptamine-4,5-dione, a putative endotoxic metabolite of the superoxide-mediated oxidation of serotonin, is a mitochondrial toxin: possible implications in neurodegenerative brain disorders. , 1999, Chemical research in toxicology.
[326] U. McCann,et al. Cognitive performance in (±) 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) users: a controlled study , 1999, Psychopharmacology.
[327] M. Christie,et al. The Anxiogenic-Like and Anxiolytic-Like Effects of MDMA on Mice in the Elevated Plus-Maze A Comparison With Amphetamine , 1999, Pharmacology Biochemistry and Behavior.
[328] S. Yeh. N‐tert‐butyl‐alpha‐phenylnitrone protects against 3,4‐methylenedioxymethamphetamine‐induced depletion of serotonin in rats , 1999, Synapse.
[329] M. Schwab,et al. Fatal MDMA intoxication , 1999, The Lancet.
[330] M. Colado,et al. In vivo evidence against clomethiazole being neuroprotective against MDMA (‘ecstasy’)-induced degeneration of rat brain 5-HT nerve terminals by a free radical scavenging mechanism , 1999, Neuropharmacology.
[331] R. Weinshilboum,et al. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. , 1999, Annual review of pharmacology and toxicology.
[332] U. McCann,et al. Memory impairment in abstinent MDMA ("Ecstasy") users , 1998, Neurology.
[333] P. Vreken,et al. Nomenclature for human DPYD alleles. , 1998, Pharmacogenetics.
[334] M. Shankaran,et al. Effect of 3,4-Methylenedioxymethamphetamine (MDMA) on Hippocampal Dopamine and Serotonin , 1998, Pharmacology Biochemistry and Behavior.
[335] A. Lees,et al. Conjugates of Catecholamines with Cysteine and GSH in Parkinson's Disease: Possible Mechanisms of Formation Involving Reactive Oxygen Species , 1998, Journal of neurochemistry.
[336] Z. Szabo,et al. Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings , 1998, The Lancet.
[337] H. Kleiner,et al. Immunochemical detection of quinol--thioether-derived protein adducts. , 1998, Chemical research in toxicology.
[338] E. Azmitia,et al. Characterization of the Translocation of Protein Kinase C (PKC) by 3,4-methylenedioxymethamphetamine (MDMA/Ecstasy) in Synaptosomes: Evidence for a Presynaptic Localization Involving the Serotonin Transporter (SERT) , 1998, Neuropsychopharmacology.
[339] F. Vollenweider,et al. Psychological and Cardiovascular Effects and Short-Term Sequelae of MDMA (“Ecstasy”) in MDMA-Naïve Healthy Volunteers , 1998, Neuropsychopharmacology.
[340] P. Reuter. World drug report , 1998 .
[341] J. del Río,et al. The role of dopaminergic systems in the perinatal sensitivity to 3, 4-methylenedioxymethamphetamine-induced neurotoxicity in rats. , 1998, The Journal of pharmacology and experimental therapeutics.
[342] M. Gill,et al. MDMA toxicity: no evidence for a major influence of metabolic genotype at CYP2D6 , 1998, Addiction biology.
[343] R. Dafters,et al. Persistent loss of thermoregulation in the rat induced by 3,4-methylenedioxymethamphetamine (MDMA or “Ecstasy”) but not by fenfluramine , 1998, Psychopharmacology.
[344] M. Colado,et al. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA (`ecstasy') , 1998, Neuropharmacology.
[345] L. Seiden,et al. Small Changes in Ambient Temperature Cause Large Changes in 3,4-Methylenedioxymethamphetamine (MDMA)-Induced Serotonin Neurotoxicity and Core Body Temperature in the Rat , 1998, The Journal of Neuroscience.
[346] M. Forsling,et al. Low-dose MDMA (“ecstasy”) induces vasopressin secretion , 1998, The Lancet.
[347] Yiwen Zheng,et al. Role of brain nitric oxide in (±)3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity in rats 1 Part of the work in this paper has been published as an abstract at 14th Australasian Winter Conference on Brain Research, Sept. 1996. 1 , 1998, Brain Research.
[348] M. Colado,et al. Role of hyperthermia in the protective action of clomethiazole against MDMA (‘ecstasy’)‐induced neurodegeneration, comparison with the novel NMDA channel blocker AR‐R15896AR , 1998, British journal of pharmacology.
[349] D E Nichols,et al. An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. , 1998, Neurotoxicology.
[350] P. Kalivas,et al. MDMA Elicits Behavioral and Neurochemical Sensitization in Rats , 1998, Neuropsychopharmacology.
[351] G. Dryhurst,et al. Oxidation of serotonin by superoxide radical: implications to neurodegenerative brain disorders. , 1998, Chemical research in toxicology.
[352] J. del Río,et al. MDMA ('Ecstasy') enhances 5-HT1A receptor density and 8-OH-DPAT-induced hypothermia: blockade by drugs preventing 5-hydroxytryptamine depletion. , 1998, European journal of pharmacology.
[353] J. O'Callaghan,et al. Immunohistochemical localization and quantification of glial fibrillary acidic protein and synaptosomal-associated protein (mol. wt 25 000) in the ageing hippocampus following administration of 5,7-dihydroxytryptamine , 1998, Neuroscience.
[354] P. Huang,et al. Resistance of neuronal nitric oxide synthase-deficient mice to methamphetamine-induced dopaminergic neurotoxicity. , 1998, The Journal of pharmacology and experimental therapeutics.
[355] M. Ratain,et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. , 1998, The Journal of clinical investigation.
[356] F. Gonzalez,et al. Molecular basis of the Dark Agouti rat drug oxidation polymorphism: importance of CYP2D1 and CYP2D2. , 1998, Pharmacogenetics.
[357] R. Blakely,et al. Phosphorylation and Regulation of Antidepressant-sensitive Serotonin Transporters* , 1998, The Journal of Biological Chemistry.
[358] D. Franchini,et al. Neuroendocrine responses of healthy volunteers to 'techno-music': relationships with personality traits and emotional state. , 1998, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.
[359] J. Kelly,et al. Acute 3,4-methylenedioxymethamphetamine(MDMA) administration produces a rapid and sustained suppression of immune function in the rat. , 1998, Immunopharmacology.
[360] M. Ingelman-Sundberg,et al. Characterization of a human glutathione S-transferase mu cluster containing a duplicated GSTM1 gene that causes ultrarapid enzyme activity. , 1997, Molecular pharmacology.
[361] D. Kuhn,et al. Molecular Mechanism of the Inactivation of Tryptophan Hydroxylase by Nitric Oxide: Attack on Critical Sulfhydryls that Spare the Enzyme Iron Center , 1997, The Journal of Neuroscience.
[362] A. Mallick,et al. MDMA induced hyperthermia: a survivor with an initial body temperature of 42.9 degrees C. , 1997, Journal of accident & emergency medicine.
[363] A. Deutch,et al. Serotonin 5‐HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex , 1997, Synapse.
[364] E. Azmitia,et al. Activation of Protein Kinase C (PKC) by 3,4-Methylenedioxymethamphetamine (MDMA) Occurs Through the Stimulation of Serotonin Receptors and Transporter , 1997, Neuropsychopharmacology.
[365] M. M. Taylor,et al. Assessment of the MDA and MDMA Optical Isomers in a Stimulant-Hallucinogen Discrimination , 1997, Pharmacology Biochemistry and Behavior.
[366] M. Gobbi,et al. Carrier‐dependent and Ca2+‐dependent 5‐HT and dopamine release induced by (+)‐amphetamine, 3,4‐methylendioxy‐methamphetamine, p‐chloroamphetamine and (+)‐fenfluramine , 1997, British journal of pharmacology.
[367] M. Colado,et al. In vivo evidence for free radical involvement in the degeneration of rat brain 5‐HT following administration of MDMA (‘ecstasy’) and p‐chloroamphetamine but not the degeneration following fenfluramine , 1997, British journal of pharmacology.
[368] M. Colado,et al. A study of the neurotoxic effect of MDMA (‘ecstasy’) on 5‐HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy , 1997, British journal of pharmacology.
[369] E. Sellers,et al. Interactions of amphetamine analogs with human liver CYP2D6. , 1997, Biochemical pharmacology.
[370] J. Cocores,et al. Neuropsychiatric manifestations following the use of 3, 4-methylenedioxymethamphetamine (MDMA; “Ecstasy”) , 1997, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[371] J. Kelly,et al. An appraisal of the pharmacological and toxicological effects of a single oral administration of 3,4-methylenedioxymethamphetamine (MDMA) in the rat. , 1997, Pharmacology & toxicology.
[372] Andrew C. Parrott,et al. Ecstasy (MDMA) in Recreational Users: Self‐Reported Psychological and Physiological Effects , 1997 .
[373] J. Buolamwini,et al. Molecular Cloning, Characterization, and Expression in Escherichia coli of Full-length cDNAs of Three Human Glutathione S-Transferase Pi Gene Variants , 1997, The Journal of Biological Chemistry.
[374] R. T. Miller,et al. 2,5-Bis-(glutathion-S-yl)-alpha-methyldopamine, a putative metabolite of (+/-)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations. , 1997, European journal of pharmacology.
[375] K. Finnegan,et al. Nitric oxide and the neurotoxic effects of methamphetamine and 3,4-methylenedioxymethamphetamine. , 1997, The Journal of pharmacology and experimental therapeutics.
[376] J. Brockmöller,et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. , 1997, American journal of human genetics.
[377] J. Buolamwini,et al. Molecular Cloning, Characterization, and Expression in Escherichia coli of Full-length cDNAs of Three Human Glutathione S -Transferase Pi Gene Variants EVIDENCE FOR DIFFERENTIAL CATALYTIC ACTIVITY OF THE ENCODED PROTEINS* , 1997 .
[378] M. Ingelman-Sundberg,et al. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. , 2003, British journal of clinical pharmacology.
[379] M. Colado,et al. The spin trap reagent PBN attenuates degeneration of 5-HT neurones in rat brain induced by p-chloroamphetamine but not fenfluramine , 1996, Neuropharmacology.
[380] U. McCann,et al. Adverse Reactions with 3,4-Methylenedioxymethamphetamine (MDMA; ‘Ecstasy’) , 1996, Drug safety.
[381] T. Obradović,et al. Methylenedioxymethamphetamine-induced inhibition of neuronal firing in the nucleus accumbens is mediated by both serotonin and dopamine , 1996, Neuroscience.
[382] L. Seiden,et al. Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. , 1996, The Journal of pharmacology and experimental therapeutics.
[383] M Ingelman-Sundberg,et al. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. , 1996, The Journal of pharmacology and experimental therapeutics.
[384] G. Dryhurst,et al. Further insights into the influence of L-cysteine on the oxidation chemistry of dopamine: reaction pathways of potential relevance to Parkinson's disease. , 1996, Chemical research in toxicology.
[385] R. Weinshilboum,et al. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. , 1996, Pharmacogenetics.
[386] A. Cho,et al. Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. , 1996, Biochemical pharmacology.
[387] B. Burchell,et al. Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome , 1996, The Lancet.
[388] R. T. Miller,et al. Effects of intracerebroventricular administration of 5-(glutathion-S-yl)-alpha-methyldopamine on brain dopamine, serotonin, and norepinephrine concentrations in male Sprague-Dawley rats. , 1996, Chemical research in toxicology.
[389] J. Richards,et al. Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part II: Radioligand binding and autoradiography studies. , 1996, The Journal of pharmacology and experimental therapeutics.
[390] J. Richards,et al. Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part I: Synaptosomal uptake and tissue concentrations. , 1996, The Journal of pharmacology and experimental therapeutics.
[391] A. Forrest,et al. Pathology of deaths associated with "ecstasy" and "eve" misuse. , 1996, Journal of clinical pathology.
[392] G. Gudelsky,et al. Carrier‐Mediated Release of Serotonin by 3,4‐Methylenedioxymethamphetamine: Implications for Serotonin‐Dopamine Interactions , 1996, Journal of neurochemistry.
[393] C. Piantadosi,et al. Brain Temperature Alters Hydroxyl Radical Production during Cerebral Ischemia/Reperfusion in Rats , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[394] J. Kelly,et al. Some behavioural and neurochemical aspects of subacute (±)3,4-methylenedioxymethamphetamine administration in rats , 1995, Pharmacology Biochemistry and Behavior.
[395] C. Wichems,et al. Release of serotonin induced by 3,4-methylenedioxymethamphetamine (MDMA) and other substituted amphetamines in cultured fetal raphe neurons: further evidence for calcium-independent mechanisms of release , 1995, Brain Research.
[396] W. Slikker,et al. Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (+/-)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response. , 1995, The Journal of pharmacology and experimental therapeutics.
[397] B. Lin,et al. Detection of Free Radical Activity During Transient Global Ischemia and Recirculation: Effects of Intraischemic Brain Temperature Modulation , 1995, Journal of neurochemistry.
[398] J. Tenhunen,et al. Cloning, expression and structure of catechol-O-methyltransferase. , 1995, Biochimica et biophysica acta.
[399] G. Ricaurte,et al. Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[400] M. Colado,et al. The hyperthermic and neurotoxic effects of ‘Ecstasy’ (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype , 1995, British journal of pharmacology.
[401] M. Colado,et al. The spin trap reagent alpha-phenyl-N-tert-butyl nitrone prevents 'ecstasy'-induced neurodegeneration of 5-hydroxytryptamine neurones. , 1995, European journal of pharmacology.
[402] B. Yamamoto,et al. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. , 1995, The Journal of pharmacology and experimental therapeutics.
[403] E. Azmitia,et al. 3,4-methylenedioxymethamphetamine (‘Ecstasy’) promotes the translocation of protein kinase C (PKC): requirement of viable serotonin nerve terminals , 1995, Brain Research.
[404] D. Nichols,et al. The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. , 1995, The Journal of pharmacology and experimental therapeutics.
[405] D. Sulzer,et al. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[406] H. Keino,et al. Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome , 1995, The Lancet.
[407] I. Ulmanen,et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. , 1995, Biochemistry.
[408] J. B. Appel,et al. Assessment of the discriminative stimulus effects of the optical isomers of ecstasy (3,4‐methylenedioxymethamphetamine; MDMA) , 1995, Behavioural pharmacology.
[409] G. Dryhurst,et al. Hydroxyl Radical‐Mediated Oxidation of Serotonin: Potential Insights into the Neurotoxicity of Methamphetamine , 1995, Journal of neurochemistry.
[410] L. Seiden,et al. Role of hypothermia in the mechanism of protection against serotonergic toxicity. I. Experiments using 3,4-methylenedioxymethamphetamine, dizocilpine, CGS 19755 and NBQX. , 1995, The Journal of pharmacology and experimental therapeutics.
[411] M. Pende,et al. Does GFAP mRNA and mitochondrial benzodiazepine receptor binding detect serotonergic neuronal degeneration in rat? , 1994, Brain Research Bulletin.
[412] A. R. Green,et al. Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA (‘Ecstasy’) to rats , 1994, Neuropharmacology.
[413] J. Fitzgerald,et al. Sympathomimetic Actions of Methylenedioxymethamphetamine in Rat and Rabbit Isolated Cardiovascular Tissues , 1994, The Journal of pharmacy and pharmacology.
[414] M. Ingelman-Sundberg,et al. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. , 1994, Molecular pharmacology.
[415] P. Duffy,et al. Methylenedioxymethamphetamine depresses glutamate-evoked neuronal firing and increases extracellular levels of dopamine and serotonin in the nucleus accumbens in vivo , 1994, Neuroscience.
[416] D. E. Nichols,et al. Effect of the R(−) and S(+) isomers of MDA and MDMA on phosphotidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors , 1994, Neuroscience Letters.
[417] J. O'Callaghan,et al. Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. , 1994, The Journal of pharmacology and experimental therapeutics.
[418] J. O'Callaghan,et al. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. , 1994, The Journal of pharmacology and experimental therapeutics.
[419] L. Fogelson,et al. Metabolic and thermoregulatory responses of the rat maintained in acrylic or wire-screen cages: Implications for pharmacological studies , 1994, Physiology & Behavior.
[420] W. Evans,et al. Ethnic differences in erythrocyte catechol-O-methyltransferase activity in black and white Americans. , 1994, The Journal of pharmacology and experimental therapeutics.
[421] E. Azmitia,et al. MDMA (Ecstasy) Inhibition of MAO Type A and Type B: Comparisons with Fenfluramine and Fluoxetine (Prozac) , 1994, Neuropsychopharmacology.
[422] R. Seymour. E for Ecstasy , 1994 .
[423] H. Bolt,et al. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. , 1994, The Biochemical journal.
[424] Y. Shaham,et al. Serotonin Neurotoxicity after (±)3,4-Methylenedioxymethamphetamine (MDMA; “Ecstasy”): A Controlled Study in Humans , 1994, Neuropsychopharmacology.
[425] G. Tucker,et al. The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). , 1994, Biochemical pharmacology.
[426] A. Logan,et al. Survival following ‘Ecstasy’ ingestion with a peak temperature of 42°C , 1993 .
[427] A. Logan,et al. Survival following 'Ecstasy' ingestion with a peak temperature of 42 degrees C. , 1993, Anaesthesia.
[428] W. Streit,et al. Loss of serotonin uptake sites and immunoreactivity in rat cortex after dexfenfluramine occur without parallel glial cell reactions , 1993, Brain Research.
[429] G. Hanson,et al. Effects of ritanserin on the 3,4-methylenedioxymethamphetamine-induced decrease in striatal serotonin concentration and on the increase in striatal neurotensin and dynorphin A concentrations. , 1993, Biochemical pharmacology.
[430] R. Foltz,et al. Stereoselective disposition: enantioselective quantitation of 3,4-(methylenedioxy) methamphetamine and three of its metabolites by gas chromatography/electron capture negative ion chemical ionization mass spectrometry. , 1993, Biological mass spectrometry.
[431] G. Hanson,et al. Short-term effects of 2,4,5-trihydroxyamphetamine, 2,4,5-trihydroxymethamphetamine and 3,4-dihydroxymethamphetamine on central tryptophan hydroxylase activity. , 1993, The Journal of pharmacology and experimental therapeutics.
[432] J L Katz,et al. Serotonergic recovery after (+/-)3,4-(methylenedioxy) methamphetamine injury: observations in rats. , 1993, The Journal of pharmacology and experimental therapeutics.
[433] W. Slikker,et al. Oral administration of 3,4-methylenedioxymethamphetamine (MDMA) produces selective serotonergic depletion in the nonhuman primate. , 1993, Neurotoxicology and teratology.
[434] M. Colado,et al. 5‐HT loss in rat brain following 3, 4‐methylenedioxymethamphetamine (MDMA), p‐chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine , 1993, British journal of pharmacology.
[435] J. O'Callaghan,et al. Mapping toxicant-induced nervous system damage with a cupric silver stain: a quantitative analysis of neural degeneration induced by 3,4-methylenedioxymethamphetamine. , 1993, NIDA research monograph.
[436] M. W. Anders,et al. Brain uptake of S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine, the glutathione and cysteine S-conjugates of the neurotoxin dichloroacetylene. , 1993, Brain research. Molecular brain research.
[437] L. Seiden,et al. The N-methyl-d-aspartate antagonist MK-801 protects against serotonin depletions induced by methamphetamine 3,4-methylenedioxymethamphetamine and p-chloroamphetamine , 1992, Brain Research.
[438] J. Ricker,et al. Discriminative stimulus effects of the optical isomers of 3,4‐methylenedioxyamphetamine (MDA) , 1992, Behavioural pharmacology.
[439] A. Bindoli,et al. Biochemical and toxicological properties of the oxidation products of catecholamines. , 1992, Free radical biology & medicine.
[440] J. Henry. Ecstasy and the dance of death. , 1992, BMJ.
[441] B. Yamamoto,et al. Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3, 4-methylenedioxymethamphetamine , 1992, Brain Research.
[442] E. Azmitia,et al. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. , 1992, European journal of pharmacology.
[443] G. Ricaurte,et al. Lasting effects of (+-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. , 1992, The Journal of pharmacology and experimental therapeutics.
[444] G. Hanson,et al. Effect of flunarizine and nimodipine on the decrease in tryptophan hydroxylase activity induced by methamphetamine and 3,4-methylenedioxymethamphetamine. , 1992, The Journal of pharmacology and experimental therapeutics.
[445] P. G. Wells,et al. Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome. , 1992, Gastroenterology.
[446] K. Cunningham,et al. Lack of serotonin neurotoxicity after intraraphe microinjection of (+)-3,4-methylenedioxymethamphetamine (MDMA) , 1992, Brain Research Bulletin.
[447] C. Hyde,et al. ‘Ecstasy’ Psychosis and Flashbacks , 1991, British Journal of Psychiatry.
[448] R. Tyndale,et al. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. , 1991, Pharmacogenetics.
[449] S. Yeh,et al. The neurochemical and stimulatory effects of putative metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine in rats , 1991, Pharmacology Biochemistry and Behavior.
[450] U. McCann,et al. Major metabolites of(±)3,4-methylenedioxyamphetamine (MDA) do not mediate its toxic effects on brain serotonin neurons , 1991, Brain Research.
[451] J. O'Callaghan,et al. Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat , 1991, Pharmacology Biochemistry and Behavior.
[452] C. J. Schmidt,et al. Selective 5-hydroxytryptamine2 receptor antagonists protect against the neurotoxicity of methylenedioxymethamphetamine in rats. , 1990, The Journal of pharmacology and experimental therapeutics.
[453] R. Poland. Diminished corticotropin and enhanced prolactin responses to 8-hydroxy-2(DI-n-propylamino)tetralin in methylenedioxymethamphetamine pretreated rats , 1990, Neuropharmacology.
[454] M. Wilson,et al. Neurotoxicity of MDMA and Related Compounds: Anatomic Studies a , 1990, Annals of the New York Academy of Sciences.
[455] A. Cho,et al. Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. , 1990, The Journal of pharmacology and experimental therapeutics.
[456] C. J. Schmidt,et al. Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine. , 1990, European journal of pharmacology.
[457] C. J. Schmidt,et al. Reversal of the acute effects of 3,4-methylenedioxymethamphetamine by 5-HT uptake inhibitors. , 1990, European journal of pharmacology.
[458] E. Azmitia,et al. MDMA (ecstasy) effects on cultured serotonergic neurons: evidence for Ca2+-dependent toxicity linked to release , 1990, Brain Research.
[459] B. Freeman,et al. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[460] T. Insel,et al. 3,4-Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys. , 1989, The Journal of pharmacology and experimental therapeutics.
[461] B. Yamamoto,et al. Acute and subchronic effects of methylenedioxymethamphetamine [(±)MDMA] on locomotion and serotonin syndrome behavior in the rat , 1989, Pharmacology Biochemistry and Behavior.
[462] G. Hanson,et al. Acute inactivation of tryptophan hydroxylase by amphetamine analogs involves the oxidation of sulfhydryl sites. , 1989, European journal of pharmacology.
[463] W. Pearson,et al. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[464] G. Hanson,et al. Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. , 1988, The Journal of pharmacology and experimental therapeutics.
[465] J. B. Appel,et al. Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4- methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline. , 1988, The Journal of pharmacology and experimental therapeutics.
[466] G. Battaglia,et al. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[467] W. Slikker,et al. Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). , 1988, Toxicology and applied pharmacology.
[468] M. Wilson,et al. (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. , 1988, JAMA.
[469] H. Meltzer,et al. Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. , 1988, The Journal of pharmacology and experimental therapeutics.
[470] E. D. De Souza,et al. Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. , 1988, European journal of pharmacology.
[471] J. Langston,et al. Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration , 1988, Brain Research.
[472] B. Yamamoto,et al. The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. , 1988, European journal of pharmacology.
[473] G. Hanson,et al. Effects of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine isomers on central serotonergic, dopaminergic and nigral neurotensin systems of the rat. , 1988, The Journal of pharmacology and experimental therapeutics.
[474] G. Battaglia,et al. MDMA-induced neurotoxicity: Parameters of degeneration and recovery of brain serotonin neurons , 1988, Pharmacology Biochemistry and Behavior.
[475] C. J. Schmidt,et al. Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. , 1987, Biochemical pharmacology.
[476] G. Hanson,et al. Differences in the central serotonergic effects of Methylenedioxymethamphetamine (MDMA) in mice and rats , 1987, Neuropharmacology.
[477] E. D. De Souza,et al. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. , 1987, The Journal of pharmacology and experimental therapeutics.
[478] L S Seiden,et al. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. , 1987, The Journal of pharmacology and experimental therapeutics.
[479] W. Lovenberg,et al. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. , 1987, Biochemical pharmacology.
[480] G. Hanson,et al. A comparison of the neurotoxic potential of methylenedioxyamphetamine (MDA) and its N-methylated and N-ethylated derivatives. , 1987, European journal of pharmacology.
[481] C. J. Schmidt,et al. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. , 1987, The Journal of pharmacology and experimental therapeutics.
[482] M. P. Johnson,et al. Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. , 1986, European journal of pharmacology.
[483] G. Hanson,et al. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. , 1986, European journal of pharmacology.
[484] J. Bakalar,et al. Can drugs be used to enhance the psychotherapeutic process? , 1986, American journal of psychotherapy.
[485] W. Lovenberg,et al. Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue. , 1986, European journal of pharmacology.
[486] R. Strassman,et al. Information on "Ecstasy". , 2006, The American journal of psychiatry.
[487] L. Seiden,et al. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. , 1985, Science.
[488] K. Tipton,et al. Deamination of 5‐Hydroxytryptamine by Both Forms of Monoamine Oxidase in the Rat Brain , 1982, Journal of neurochemistry.
[489] T. Alexander,et al. CHARACTERIZATION OF THREE NEW PSYCHOTOMIMETICS , 1978 .
[490] A. Björklund,et al. Neurotoxic indoleamines and monoamine neurons. , 1976, Annual Review of Pharmacology and Toxicology.